Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27FO6 |
Molecular Weight | 394.4339 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=GFNANZIMVAIWHM-OBYCQNJPSA-N
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
Molecular Formula | C21H27FO6 |
Molecular Weight | 394.4339 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19744340 |
1.5 nM [IC50] | ||
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D00984 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7202 ng/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1911 ng × h/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.7 day |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
120 mg 1 times / day multiple, intramuscular Higher than recommended Dose: 120 mg, 1 times / day Route: intramuscular Route: multiple Dose: 120 mg, 1 times / day Sources: Page: p.588 |
unhealthy, 28-57 n = 12 Health Status: unhealthy Condition: Asthma Age Group: 28-57 Sex: M+F Population Size: 12 Sources: Page: p.588 |
|
360 mg single, intramuscular Highest studied dose Dose: 360 mg Route: intramuscular Route: single Dose: 360 mg Sources: Page: p.1465 |
unhealthy, 37.5 n = 6 Health Status: unhealthy Condition: Asthma Age Group: 37.5 Sex: M+F Population Size: 6 Sources: Page: p.1465 |
|
200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: Page: p.13 |
unhealthy, 46 n = 1 Health Status: unhealthy Condition: Bursitis Age Group: 46 Sex: F Population Size: 1 Sources: Page: p.13 |
Disc. AE: Cushing's syndrome... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: Page: p.13 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cushing's syndrome | Disc. AE | 200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: Page: p.13 |
unhealthy, 46 n = 1 Health Status: unhealthy Condition: Bursitis Age Group: 46 Sex: F Population Size: 1 Sources: Page: p.13 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10570047/ |
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. Page: 10.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Symptomatic spinal epidural lipomatosis after local epidural corticosteroid injections: case report. | 1999 Jul |
|
[Experiences with liposuction of established surgeons]. | 2001 |
|
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? | 2001 |
|
Gray ramus communicans nerve block: novel treatment approach for painful osteoporotic vertebral compression fracture. | 2001 Apr |
|
Combined treatment of a proliferative peri-orbital haemangioma with a tuneable dye laser and intra-lesional steroids to prevent deprivation amblyopia. | 2001 Aug |
|
Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. | 2001 Dec |
|
Intralesional corticosteroid injection for treatment of central giant-cell granuloma. | 2001 Feb |
|
Isolated tuberculous monoarthritis mimicking oligoarticular juvenile rheumatoid arthritis. | 2001 Jan |
|
Steroid allergy: report of two cases. | 2001 Jun |
|
Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. | 2001 Mar |
|
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. | 2001 May |
|
High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas. | 2001 May |
|
Plasma cell mucositis. | 2001 Nov |
|
Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice. | 2001 Nov |
|
Cushing syndrome induced by serial occipital nerve blocks containing corticosteroids. | 2001 Oct |
|
Experience with difficult keloids. | 2001 Oct |
|
[The effect of triamcinolone, montelukast and formoterol on serum levels of il-4, IgE and clinical parameters in children with asthma]. | 2001 Sep |
|
Treatment of childhood phimosis with a moderately potent topical steroid. | 2001 Sep |
|
Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. | 2001 Summer |
|
Two cases of morphea associated with Hashimoto's thyroiditis. | 2002 |
|
Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients. | 2002 Apr |
|
A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. | 2002 Feb |
|
Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. | 2002 Feb |
|
Subcutaneous steroid injection as treatment for chalazion: prospective case series. | 2002 Feb |
|
Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. | 2002 Feb |
|
Treating patients with hemiplegic shoulder pain. | 2002 Feb |
|
Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. | 2002 Jan |
|
Selective corticosteroid injection into the extensor pollicis brevis tenosynovium for de Quervain's disease. | 2002 Jan |
|
Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone. | 2002 Jan-Feb |
|
Salmeterol was not as effective as triamcinolone for persistent asthma. | 2002 Jan-Feb |
|
Correction of the soft tissue pollybeak using triamcinolone injection. | 2002 Jan-Mar |
|
Spontaneous bleeding following steroid injection and silicone-gel sheeting in a keloid scar. | 2002 Mar |
|
CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. | 2002 May |
|
Laser-induced weal and flare reactions: clinical aspects and pharmacological modulation. | 2002 May |
|
Intravitreal triamcinolone for refractory diabetic macular edema. | 2002 May |
|
Local injection treatment for lateral epicondylitis. | 2002 May |
|
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. | 2002 May |
Sample Use Guides
The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14406639
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:07:02 GMT 2023
by
admin
on
Sat Dec 16 05:07:02 GMT 2023
|
Record UNII |
1ZK20VI6TY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QH02AB08
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QA01AC01
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
D07BB03
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
LIVERTOX |
994
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
R03BA06
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
CFR |
21 CFR 524.1600B
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
CFR |
21 CFR 522.2483
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QR01AD11
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QD07AB09
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
A01AC01
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
CFR |
21 CFR 524.2483
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
D07XB02
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
R01AD11
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
H02AB08
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
CFR |
21 CFR 524.2482
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QD07CB01
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
CFR |
21 CFR 524.1600A
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QD07BB03
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QD07XB02
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
S02CA04
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QC05AA12
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
CFR |
21 CFR 520.2483
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QR03BA06
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
D07CB01
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QS01BA05
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-VATC |
QS02CA04
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
S01BA05
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
C05AA12
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
||
|
WHO-ATC |
D07AB09
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C901
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
2725
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
100000092178
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
755
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
TRIAMCINOLONE
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
Triamcinolone, Topical
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
DB00620
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
124-94-7
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
m11027
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
2870
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
SUB11251MIG
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL1451
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
1676000
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
9667
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
Triamcinolone
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
10759
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | RxNorm | ||
|
13397
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
31307
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
DTXSID1040742
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
3194
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
204-718-7
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY | |||
|
D014221
Created by
admin on Sat Dec 16 05:07:02 GMT 2023 , Edited by admin on Sat Dec 16 05:07:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
TARGET -> AGONIST |
BINDING
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|